Teva prices $4.9B senior notes to refinance higher-coupon debt

TEVA PHARMACEUTICAL INDUSTRIES LTD

EUR tranches: €1.0B 4.250% due 2033, €500M 4.625% due 2036.
USD tranches: $1.0B 5.500% due 2034, $1.0B 5.750% due 2037, $1.2B 5.250% due 2032.
Closing expected Sept 16, 2026; senior unsecured, guaranteed by Teva.
Proceeds fund redemptions: all 6.750% 2028, 7.875% 2029, 7.375% 2029, up to $450M 4.750% 2027, €1.25B 4.375% 2030 (reduced to €1.15B).
Also plans to redeem all 8.125% 2031 notes; remainder for general corporate purposes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.